Entera Bio Ltd. (ENTX) SEC Filings, Aug 4-7, 2026

Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. granted Chief Operating Officer Hillel Galitzer stock options to buy 200,000 ordinary shares at $1.3700 per share, expiring 2036-05-07. The Board approved the grant on May 7, 2026, contingent on a Form S-8 registration that became effective August 7, 2026. The options vest over three years starting May 7, 2026, with one third vesting on May 7, 2027 and the remaining two-thirds vesting quarterly, subject to full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.

Entera Bio Ltd. granted its Chief of R&D, Gregory Burshtein, 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share. The options expire on May 7, 2036 and vest over three years starting May 7, 2026, with full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.

Entera Bio Ltd. granted its Chief Executive Officer, Miranda Jayne Toledano, two stock option awards reported as derivative acquisitions on August 7, 2026. One award covers 500,000 ordinary shares at a $1.37 exercise price expiring on May 6, 2036; the other covers 200,000 shares at $2.81 expiring on August 7, 2036.

The 500,000-share grant was approved by the board and shareholders in 2026 and vests over three years beginning May 7, 2026, with one-third vesting on May 7, 2027 and full acceleration upon a Change in Control under the 2018 Equity Incentive Plan. The 200,000-share grant was originally approved in 2022, became effective after a July 2026 financing transaction that funded a Phase 3 trial, and vests over four years starting August 7, 2026, with 25% vesting on the first anniversary and the balance vesting quarterly.

Entera Bio Ltd. director Germano Geno J reported equity compensation. He received 25,014 ordinary shares on August 7, 2026 in lieu of cash director fees for the first two quarters of 2026, raising his direct holdings to 65,014 shares. He was also granted stock options for 50,000 and 43,014 ordinary shares at an exercise price of 1.3700 per share, expiring May 7, 2036 and vesting over one- and three-year schedules starting February 4, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.

Entera Bio Ltd., a clinical-stage developer of oral peptide therapies, reported higher losses as it advanced its lead osteoporosis candidate EB613 and partnered programs EB612 and EB618. For the six months ended June 30, 2026, the company recorded no revenue, research and development expenses of $5.5 million and a net loss of $10.8 million, up from $5.2 million a year earlier, driven by increased development spending and a non-cash remeasurement of pre-funded warrant liabilities.

Cash, cash equivalents and restricted cash totaled $18.5 million at June 30, 2026. In July 2026, Entera completed a private placement raising about $275 million, and the company states that, together with existing cash, this is expected to fund planned operations, including a single Phase 3 EB613 trial in roughly 750 postmenopausal women with osteoporosis and continued advancement of EB612 and EB618 with OPKO, into 2030.

Entera Bio Ltd. reported second-quarter 2026 results and major financing and pipeline milestones. For the three months ended June 30, 2026, the company generated no revenue, incurred research and development expenses of $3.2 million and general and administrative expenses of $1.4 million. Net loss was $7.3 million, or $0.14 per share, compared with $2.7 million, or $0.06 per share, a year earlier, driven in part by a $2.7 million non-cash fair value remeasurement of pre-funded warrants issued in April 2026. As of June 30, 2026, cash and cash equivalents were $11.3 million and restricted cash was $7.1 million.

The company highlighted U.S. FDA alignment on a 12‑month registrational Phase 3 study of EB613 for osteoporosis, with study initiation planned for late 2026 and topline data anticipated in the second half of 2028, to support a New Drug Application. Entera completed an oversubscribed $275.0 million private placement led by BVF Partners L.P., which it expects will fully fund the EB613 Phase 3 program through topline results and anticipated NDA submission and support operations into 2030. IND-enabling studies are ongoing for EB612 for hypoparathyroidism, with an IND filing intended in the first half of 2027, alongside additional oral peptide programs EB618 and an oral GLP‑2 tablet in collaboration with OPKO Health.

Entera Bio Ltd. has a significant shareholder group led by Longitude Venture Partners V, L.P., which is the record owner of 7,843,138 ordinary shares. Based on 172,251,411 ordinary shares outstanding as of July 28, 2026, the filing reports this position as 4.6% of the class for each Reporting Person.

Longitude Capital Partners V, LLC is the general partner of LVPV, and Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCPV; each may be deemed to share voting and dispositive power over these shares, while disclaiming beneficial ownership except to the extent of pecuniary interest. The filing also notes that Seven Fleet may be deemed to beneficially own 7,053,898 ordinary shares, or 4.1%, under certain policies and procedures, though group status and related beneficial ownership are expressly disclaimed.

Entera Bio, Ltd. is reported to have significant ownership by investment funds managed by Seven Fleet Capital Management and by Brian Liu. Seven Fleet Horizon Master Fund is the record owner of 1,960,784 Ordinary Shares, and Seven Fleet Master Fund holds 5,093,114 Ordinary Shares, for an aggregate of 7,053,898 Ordinary Shares that Seven Fleet Capital Management, its general partner, and Brian Liu may be deemed to beneficially own. This stake represents 4.1% of the 172,251,411 Ordinary Shares outstanding as of July 28, 2026, with only shared, not sole, voting and dispositive power reported. The disclosure also notes that Longitude Capital Management and its affiliates may be deemed to beneficially own 7,843,138 Ordinary Shares, or 4.6% of the class, under policies and procedures that could cause them and the Seven Fleet entities to be viewed as a group, while all such parties expressly disclaim group status and certain beneficial ownership.

Biotechnology Value Fund and affiliated entities report beneficial ownership of 17,225,121 ordinary shares of Entera Bio Ltd. (9.99% of outstanding shares), accumulated through significant April and July 2026 financings and related investments using working capital.

In April 2026, Entera completed a private placement of 7,827,789 units for approximately $10.0 million at $1.2775 per unit, each unit comprising one share (or an April pre-funded warrant) and a warrant for 1.5 shares. In July 2026, Entera raised approximately $275.0 million by selling 134,803,910 shares (or July pre-funded warrants) at $2.04 per share, issuing 14,627,893 shares and 11,842,695 July pre-funded warrants to the reporting group.

The investors also hold April and July pre-funded warrants and standard warrants covering tens of millions of shares, subject to 4.99% and 9.99% beneficial ownership blockers that currently restrict exercise. Under the July agreement, the group may designate up to two directors to Enteras board while maintaining specified ownership thresholds and has agreed to support proposals increasing the 2018 equity plan and restoring executive ownership percentages.